Valuation: Roche Holding AG

Market Cap 267B 330B 289B 247B 468B 31,592B 477B 3,212B 1,248B 15,460B 1,239B 1,212B 53,667B P/E 2026 *
17.8x
P/E 2027 * 16.7x
Enterprise Value 278B 343B 301B 257B 486B 32,841B 496B 3,339B 1,297B 16,071B 1,288B 1,260B 55,789B EV / Sales 2026 *
4.43x
EV / Sales 2027 * 4.16x
Free-Float
88.78%
Yield 2026 *
2.99%
Yield 2027 * 3.06%
Current month+0.48%
6 months-4.36%
Current year-1.29%
Current year 311.6
Extreme 311.6
377
1 year 221.3
Extreme 221.3
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 336B
-1.60%+2.02%+56.34%+168.94% 1,102B
-1.44%+3.71%+69.07%+65.40% 643B
-0.75%+0.67%+33.18%+86.52% 450B
-0.86%+0.99%+39.36%+40.85% 298B
-0.71%-0.54%+28.98%+48.27% 288B
-1.31%+2.72%-26.76%-39.82% 222B
-0.03%+1.84%+23.90%+68.30% 199B
-0.40%+7.82%+22.29%+82.50% 169B
-0.08%+0.71%-6.13%-32.31% 137B
Average -0.72%+2.81%+26.70%+54.30% 389.73B
Weighted average by Cap. -1.00%+2.70%+40.85%+87.66%

Financials

2026 *2027 *
Net sales 62.63B 77.34B 67.84B 57.87B 110B 7,406B 112B 753B 293B 3,624B 290B 284B 12,581B 65.2B 80.52B 70.62B 60.25B 114B 7,710B 116B 784B 305B 3,773B 302B 296B 13,097B
Net income 15.25B 18.83B 16.52B 14.09B 26.71B 1,803B 27.24B 183B 71.23B 882B 70.72B 69.17B 3,063B 16.29B 20.12B 17.64B 15.05B 28.53B 1,926B 29.1B 196B 76.08B 943B 75.54B 73.88B 3,272B
Net Debt 10.56B 13.05B 11.44B 9.76B 18.5B 1,249B 18.87B 127B 49.34B 611B 48.99B 47.92B 2,122B 3.87B 4.77B 4.19B 3.57B 6.77B 457B 6.91B 46.48B 18.06B 224B 17.93B 17.54B 777B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
26-07-08 CHF 323.90 0.00% 6,493
26-07-07 CHF 323.90 0.00% 1,400
26-07-06 CHF 323.90 0.00% 2,786
26-07-03 CHF 323.90 0.00% 496
26-07-02 CHF 323.90 0.00% 2,593
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
334.90CHF
Average target price
359.22CHF
Spread / Average Target
+7.26%

Quarterly revenue - Rate of surprise